SG11201507364SA - Combination of two antivirals for treating hepatitis c - Google Patents

Combination of two antivirals for treating hepatitis c

Info

Publication number: SG11201507364SA
Authority: SG; Singapore
Prior art keywords: antivirals; combination; treating hepatitis; hepatitis; treating
Prior art date: 2013-03-14

Application number

SG11201507364SA

Inventor

Barry M Bernstein

Sandeep Dutta

Wei Liu

Thomas J Podsadecki

Andrew L Campbell

Rajeev M Menon

Chih-Wei Lin

Tianli Wang

Walid M Awni

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2014-03-14

Publication date

2015-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201507364S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-14 Application filed by Abbvie Inc filed Critical Abbvie Inc

2015-10-29 Publication of SG11201507364SA publication Critical patent/SG11201507364SA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11201507364SA 2013-03-14 2014-03-14 Combination of two antivirals for treating hepatitis c SG11201507364SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361783376P	2013-03-14	2013-03-14
PCT/US2014/027423 WO2014152514A1 (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c

Publications (1)

Publication Number	Publication Date
SG11201507364SA true SG11201507364SA (en)	2015-10-29

Family

ID=50588882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201507364SA SG11201507364SA (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c
SG10201708306WA SG10201708306WA (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201708306WA SG10201708306WA (en)	2013-03-14	2014-03-14	Combination of two antivirals for treating hepatitis c

Country Status (26)

Country	Link
US (1)	US20140275099A1 (en)
EP (3)	EP2968301B1 (en)
JP (4)	JP6441303B2 (en)
KR (2)	KR102210935B1 (en)
CN (2)	CN108159393A (en)
AU (2)	AU2014239563B2 (en)
BR (1)	BR112015023017B1 (en)
CA (1)	CA2901810C (en)
CY (2)	CY1119025T1 (en)
DK (2)	DK3213750T3 (en)
EA (2)	EA201991174A1 (en)
ES (2)	ES2824473T3 (en)
HK (2)	HK1223817A1 (en)
HR (2)	HRP20171036T1 (en)
HU (2)	HUE052113T2 (en)
IL (1)	IL240419B (en)
LT (2)	LT3213750T (en)
MX (2)	MX362616B (en)
NZ (2)	NZ719137A (en)
PL (2)	PL3213750T3 (en)
PT (2)	PT3213750T (en)
RS (2)	RS60881B1 (en)
SG (2)	SG11201507364SA (en)
SI (2)	SI3213750T1 (en)
TW (2)	TWI642436B (en)
WO (1)	WO2014152514A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201507364SA (en)	2013-03-14	2015-10-29	Abbvie Inc	Combination of two antivirals for treating hepatitis c
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20150011481A1 (en) *	2013-07-02	2015-01-08	Abbvie Inc.	Methods for Treating HCV
MX2016005393A (en) *	2013-10-25	2016-08-11	Abbvie Inc	Methods for treating hcv.
US20150174194A1 (en) *	2013-12-19	2015-06-25	Abbvie Inc.	Methods for treating liver transplant recipients
MX2016012722A (en) *	2014-04-02	2016-12-16	Abbvie Inc	Methods for treating hcv.
CN112891511A (en) *	2014-04-02	2021-06-04	艾伯维公司	Methods of treating HCV
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
MX2018000218A (en) *	2015-06-26	2018-03-08	Abbvie Inc	Solid pharmaceutical compositions for treating hcv.
US20230385268A1 (en) *	2022-05-17	2023-11-30	Abbvie Inc.	Methods for Treating HCV
JP6808660B2 (en) *	2015-07-08	2021-01-06	アッヴィ・インコーポレイテッド	Methods for treating HCV
CN108024964B (en) *	2015-07-17	2022-05-03	艾伯维公司	Solid pharmaceutical composition for the treatment of HCV
EP3448392A4 (en)	2016-04-28	2020-01-15	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3515442A4 (en) *	2016-09-23	2020-05-06	AbbVie Inc.	Dose adjustment
JP2018131439A (en) *	2017-02-14	2018-08-23	アッヴィ・インコーポレイテッド	Methods for treating hcv
CA2981993A1 (en) *	2017-08-02	2019-02-02	Abbvie Inc.	Methods for treating hcv
TW202012001A (en) *	2018-04-10	2020-04-01	美商亞堤製藥公司	Treatment of cirrhotic hcv infected patients
EP3883569A1 (en)	2018-11-20	2021-09-29	Abbvie Inc.	Methods for treating acute hcv
KR102077833B1 (en)	2018-12-10	2020-02-14	류형준	Fuctional food compositions
CN111688355B (en)	2019-03-15	2022-04-12	精工爱普生株式会社	Liquid absorber, and liquid ejecting apparatus
CA3136316A1 (en) *	2019-04-08	2020-10-15	Abbvie Inc.	Solid pharmaceutical compositions for treating hcv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8937150B2 (en) *	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en) *	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
AR083052A1 (en) *	2010-09-21	2013-01-30	Enanta Pharm Inc	INHIBITORS OF HCV SERINE PROTEASES DERIVED FROM MACROCICLIC PROLINES
US8330139B2 (en)	2011-03-25	2012-12-11	Micron Technology, Inc.	Multi-level memory cell
MX2014004729A (en)	2011-10-21	2014-07-28	Abbvie Inc	Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv.
TWI532487B (en)	2011-10-21	2016-05-11	艾伯維有限公司	Methods for treating hcv
HUE046544T2 (en) *	2012-09-18	2020-03-30	Abbvie Inc	Methods for treating hepatitis c
SG11201507364SA (en)	2013-03-14	2015-10-29	Abbvie Inc	Combination of two antivirals for treating hepatitis c

2014
- 2014-03-14 SG SG11201507364SA patent/SG11201507364SA/en unknown
- 2014-03-14 DK DK17165207.6T patent/DK3213750T3/en active
- 2014-03-14 TW TW103109530A patent/TWI642436B/en not_active IP Right Cessation
- 2014-03-14 KR KR1020157029549A patent/KR102210935B1/en active IP Right Grant
- 2014-03-14 EA EA201991174A patent/EA201991174A1/en unknown
- 2014-03-14 PT PT171652076T patent/PT3213750T/en unknown
- 2014-03-14 CN CN201810067970.1A patent/CN108159393A/en active Pending
- 2014-03-14 PL PL17165207T patent/PL3213750T3/en unknown
- 2014-03-14 LT LTEP17165207.6T patent/LT3213750T/en unknown
- 2014-03-14 CN CN201480015311.3A patent/CN105073113B/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020217002760A patent/KR20210013344A/en active Application Filing
- 2014-03-14 JP JP2016502431A patent/JP6441303B2/en active Active
- 2014-03-14 MX MX2015012538A patent/MX362616B/en active IP Right Grant
- 2014-03-14 PT PT147199772T patent/PT2968301T/en unknown
- 2014-03-14 ES ES17165207T patent/ES2824473T3/en active Active
- 2014-03-14 RS RS20201198A patent/RS60881B1/en unknown
- 2014-03-14 WO PCT/US2014/027423 patent/WO2014152514A1/en active Application Filing
- 2014-03-14 SI SI201431674T patent/SI3213750T1/en unknown
- 2014-03-14 DK DK14719977.2T patent/DK2968301T3/en active
- 2014-03-14 NZ NZ719137A patent/NZ719137A/en unknown
- 2014-03-14 PL PL14719977T patent/PL2968301T3/en unknown
- 2014-03-14 EP EP14719977.2A patent/EP2968301B1/en not_active Revoked
- 2014-03-14 NZ NZ631155A patent/NZ631155A/en unknown
- 2014-03-14 ES ES14719977.2T patent/ES2624980T3/en active Active
- 2014-03-14 US US14/210,870 patent/US20140275099A1/en not_active Abandoned
- 2014-03-14 TW TW107108651A patent/TWI686196B/en not_active IP Right Cessation
- 2014-03-14 SI SI201430265A patent/SI2968301T1/en unknown
- 2014-03-14 HU HUE17165207A patent/HUE052113T2/en unknown
- 2014-03-14 EP EP17165207.6A patent/EP3213750B1/en active Active
- 2014-03-14 CA CA2901810A patent/CA2901810C/en active Active
- 2014-03-14 EP EP20183791.1A patent/EP3766495A1/en active Pending
- 2014-03-14 LT LTEP14719977.2T patent/LT2968301T/en unknown
- 2014-03-14 AU AU2014239563A patent/AU2014239563B2/en active Active
- 2014-03-14 BR BR112015023017-2A patent/BR112015023017B1/en active IP Right Grant
- 2014-03-14 HU HUE14719977A patent/HUE033010T2/en unknown
- 2014-03-14 RS RS20170672A patent/RS56202B1/en unknown
- 2014-03-14 SG SG10201708306WA patent/SG10201708306WA/en unknown
- 2014-03-14 EA EA201591702A patent/EA033257B1/en unknown
2015
- 2015-08-06 IL IL240419A patent/IL240419B/en active IP Right Grant
- 2015-09-11 MX MX2020005054A patent/MX2020005054A/en unknown
2016
- 2016-05-03 AU AU2016202823A patent/AU2016202823B2/en active Active
- 2016-07-20 HK HK16108631.0A patent/HK1223817A1/en unknown
- 2016-07-20 HK HK18103210.8A patent/HK1244668A1/en unknown
2017
- 2017-06-21 CY CY20171100653T patent/CY1119025T1/en unknown
- 2017-07-06 HR HRP20171036TT patent/HRP20171036T1/en unknown
2018
- 2018-11-22 JP JP2018219054A patent/JP6621902B2/en active Active
2019
- 2019-11-19 JP JP2019208502A patent/JP2020037589A/en active Pending
2020
- 2020-10-05 CY CY20201100930T patent/CY1123387T1/en unknown
- 2020-10-05 HR HRP20201575TT patent/HRP20201575T1/en unknown
2021
- 2021-06-07 JP JP2021094935A patent/JP2021130720A/en active Pending

Also Published As

Publication number	Publication date
HRP20171036T1 (en)	2017-10-06
MX362616B (en)	2019-01-28
EP2968301A1 (en)	2016-01-20
HUE033010T2 (en)	2017-11-28
AU2016202823A1 (en)	2016-05-19
LT2968301T (en)	2017-05-25
CA2901810C (en)	2019-01-08
RS60881B1 (en)	2020-11-30
JP6441303B2 (en)	2018-12-19
PT3213750T (en)	2020-10-19
SI2968301T1 (en)	2017-07-31
SG10201708306WA (en)	2017-11-29
CA2901810A1 (en)	2014-09-25
KR20150129032A (en)	2015-11-18
EP2968301B1 (en)	2017-04-19
JP6621902B2 (en)	2019-12-18
IL240419A0 (en)	2015-09-24
NZ631155A (en)	2016-05-27
EA201591702A1 (en)	2016-09-30
TW201511759A (en)	2015-04-01
DK3213750T3 (en)	2020-10-19
TW201834656A (en)	2018-10-01
KR102210935B1 (en)	2021-02-02
CN105073113B (en)	2018-01-02
IL240419B (en)	2019-03-31
HK1223817A1 (en)	2017-08-11
TWI686196B (en)	2020-03-01
CN108159393A (en)	2018-06-15
BR112015023017A2 (en)	2017-07-18
ES2624980T3 (en)	2017-07-18
JP2016513695A (en)	2016-05-16
US20140275099A1 (en)	2014-09-18
AU2014239563A1 (en)	2015-08-27
CY1123387T1 (en)	2021-12-31
KR20210013344A (en)	2021-02-03
LT3213750T (en)	2020-10-26
PL3213750T3 (en)	2020-12-14
MX2020005054A (en)	2020-08-20
TWI642436B (en)	2018-12-01
JP2020037589A (en)	2020-03-12
AU2016202823B2 (en)	2017-11-23
MX2015012538A (en)	2016-02-10
AU2014239563B2 (en)	2016-05-05
EP3213750B1 (en)	2020-08-12
HK1244668A1 (en)	2018-08-17
EA033257B1 (en)	2019-09-30
JP2021130720A (en)	2021-09-09
HRP20201575T1 (en)	2020-12-11
SI3213750T1 (en)	2020-11-30
PL2968301T3 (en)	2017-09-29
EP3766495A1 (en)	2021-01-20
HUE052113T2 (en)	2021-04-28
NZ719137A (en)	2017-11-24
BR112015023017B1 (en)	2022-08-30
ES2824473T3 (en)	2021-05-12
JP2019048868A (en)	2019-03-28
RS56202B1 (en)	2017-11-30
DK2968301T3 (en)	2017-07-24
EA201991174A1 (en)	2020-01-31
WO2014152514A1 (en)	2014-09-25
CN105073113A (en)	2015-11-18
EP3213750A1 (en)	2017-09-06
PT2968301T (en)	2017-07-17
CY1119025T1 (en)	2018-01-10

Publication	Publication Date	Title
HK1244668A1 (en)	2018-08-17	Combination of two antivirals for treating hepatitis c
IL278912A (en)	2021-01-31	Improved compositions for treating muscular dystrophy
HK1213886A1 (en)	2016-07-15	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases n--3-
HUE050485T2 (en)	2020-12-28	Methods of treating a tauopathy
HK1209319A1 (en)	2016-04-01	Methods for treating hepatitis c
EP2968273A4 (en)	2016-08-31	Methods of treating muscular dystrophy
HK1209320A1 (en)	2016-04-01	Methods for treating hepatitis c
IL241096B (en)	2021-05-31	Method of treatment
GB201308466D0 (en)	2013-06-19	Improved process for treatment of minewater
GB201322764D0 (en)	2014-02-05	Treating places
GB201322778D0 (en)	2014-02-05	Method of treatment
GB201314882D0 (en)	2013-10-02	Method of treatment